GLENMARK THERAPEUTICS

Serial Number 77401648
606

Registration Progress

Application Filed
Feb 20, 2008
Under Examination
Apr 21, 2009
Approved for Publication
Jan 7, 2009
Published for Opposition
Jan 27, 2009
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: GLENMARK THERAPEUTICS
Previous Owner: GLENMARK THERAPEUTICS INC., USA
Classes: 005

Trademark Image

GLENMARK THERAPEUTICS

Basic Information

Serial Number
77401648
Filing Date
February 20, 2008
Published for Opposition
January 27, 2009
Abandonment Date
May 23, 2011
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
May 23, 2011
Classes
005

Rights Holder

GLENMARK THERAPEUTICS INC., USA

03
Address
750 CORPORATE DRIVE
MAHWAH, NJ 07430

Ownership History

Glenmark Pharmaceuticals Inc., USA

Original Applicant
03
Mahwah, NJ

Glenmark Pharmaceuticals Inc., USA

Owner at Publication
03
Mahwah, NJ

GLENMARK THERAPEUTICS INC., USA

New Owner After Publication #1
03
MAHWAH, NJ

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

42 events
Date Code Type Description Documents
May 23, 2011 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Loading...
May 23, 2011 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Oct 28, 2010 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 27, 2010 EX3G S SOU EXTENSION 3 GRANTED Loading...
Oct 21, 2010 EXT3 S SOU EXTENSION 3 FILED Loading...
Oct 26, 2010 TPEX I SOU EXTENSION RECEIVED WITH TEAS PETITION Loading...
Oct 26, 2010 PETG O PETITION TO REVIVE-GRANTED Loading...
Oct 26, 2010 PROA I TEAS PETITION TO REVIVE RECEIVED Loading...
May 21, 2010 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 20, 2010 EX2G S SOU EXTENSION 2 GRANTED Loading...
Apr 21, 2010 EXT2 S SOU EXTENSION 2 FILED Loading...
May 19, 2010 TPEX I SOU EXTENSION RECEIVED WITH TEAS PETITION Loading...
May 19, 2010 PETG O PETITION TO REVIVE-GRANTED Loading...
May 19, 2010 PROA I TEAS PETITION TO REVIVE RECEIVED Loading...
Mar 3, 2010 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Mar 2, 2010 EX1G S SOU EXTENSION 1 GRANTED Loading...
Oct 21, 2009 EXT1 S SOU EXTENSION 1 FILED Loading...
Mar 1, 2010 PGEX O PETITION GRANTED - EXTENSION REQUEST FILED Loading...
Feb 3, 2010 PINM O INCOMPLETE PETITION NOTICE MAILED Loading...
Feb 2, 2010 APET A ASSIGNED TO PETITION STAFF Loading...
Dec 1, 2009 PETR I PETITION TO REVIVE-RECEIVED Loading...
Feb 1, 2010 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Dec 1, 2009 TPEX I SOU EXTENSION RECEIVED WITH TEAS PETITION Loading...
Dec 1, 2009 PETG O PETITION TO REVIVE-GRANTED Loading...
Dec 1, 2009 PROA I TEAS PETITION TO REVIVE RECEIVED Loading...
Nov 23, 2009 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Loading...
Nov 23, 2009 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Apr 21, 2009 NOAM O NOA MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jan 27, 2009 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 7, 2009 NPUB O NOTICE OF PUBLICATION Loading...
Dec 22, 2008 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Dec 16, 2008 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 15, 2008 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 15, 2008 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 15, 2008 ALIE A ASSIGNED TO LIE Loading...
Dec 1, 2008 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 2, 2008 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 2, 2008 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jun 2, 2008 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jun 2, 2008 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 27, 2008 MPMK O NOTICE OF PSEUDO MARK MAILED Loading...
Feb 26, 2008 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Preparation for the relief of pain
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Pseudo Mark
GLEN MARK THERAPEUTICS

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"THERAPEUTICS"